Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023 - 2026)
Contineum Therapeutics' (CTNM) quarterly Amortization of Deferred Charges came in at $624000.0 in Q1 2026, up 167.81% year-on-year from $233000.0 in Q1 2025, and up 61.24% quarter-over-quarter from $387000.0 in Q4 2025.
Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $624000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 167.81% year-over-year to $624000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 70.85% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 23.85% from the prior year.
- Amortization of Deferred Charges grew to $624000.0 in Q1 2026 per CTNM's latest filing, from $387000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $624000.0 in Q1 2026 and bottomed at -$899000.0 in Q4 2023.
- The 4-year median for Amortization of Deferred Charges is $233000.0 (2025), against an average of $182923.1.
- Biggest YoY gain for Amortization of Deferred Charges was 838.46% in 2024; the steepest drop was 44.67% in 2024.
- Year by year, Amortization of Deferred Charges stood at -$899000.0 in 2023, then surged by 117.02% to $153000.0 in 2024, then jumped by 152.94% to $387000.0 in 2025, then soared by 61.24% to $624000.0 in 2026.
- Per Business Quant, the three latest CTNM Amortization of Deferred Charges figures stand at $624000.0 (Q1 2026), $387000.0 (Q4 2025), and $233000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Contineum Therapeutics | 523.31 Mn | 523.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 624,000.00 |
| Mar 31, 2026 | 624,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 244,000.00 |
| Mar 31, 2024 | 244,000.00 |
| Dec 31, 2023 | -899,000.00 |
| Dec 31, 2023 | -899,000.00 |